Pivotal Bioventure Partners Fund I G.p., L.p. - Net Worth and Insider Trading
Pivotal Bioventure Partners Fund I G.p., L.p. Net Worth
The estimated net worth of Pivotal Bioventure Partners Fund I G.p., L.p. is at least $34 Million dollars as of 2024-05-05. Pivotal Bioventure Partners Fund I G.p., L.p. is the 10% Owner of Akouos Inc and owns about 1,794,088 shares of Akouos Inc (AKUS) stock worth over $24 Million. Pivotal Bioventure Partners Fund I G.p., L.p. is the Director of Inozyme Pharma Inc and owns about 1,571,741 shares of Inozyme Pharma Inc (INZY) stock worth over $7 Million. Pivotal Bioventure Partners Fund I G.p., L.p. is also the 10% Owner of Entasis Therapeutics Holdings Inc and owns about 1,180,178 shares of Entasis Therapeutics Holdings Inc (ETTX) stock worth over $3 Million. Details can be seen in Pivotal Bioventure Partners Fund I G.p., L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Pivotal Bioventure Partners Fund I G.p., L.p. has not made any transactions after 2023-08-01 and currently still holds the listed stock(s).
Transaction Summary of Pivotal Bioventure Partners Fund I G.p., L.p.
Pivotal Bioventure Partners Fund I G.p., L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Pivotal Bioventure Partners Fund I G.p., L.p. owns 3 companies in total, including Inozyme Pharma Inc (INZY) , Akouos Inc (AKUS) , and Entasis Therapeutics Holdings Inc (ETTX) .
Insider Ownership Summary of Pivotal Bioventure Partners Fund I G.p., L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| INZY | Inozyme Pharma Inc | 2023-08-01 | director |
| AKUS | Akouos Inc | 2020-06-30 | 10 percent owner |
| ETTX | Entasis Therapeutics Holdings Inc | 2018-09-28 | 10 percent owner |
Pivotal Bioventure Partners Fund I G.p., L.p. Latest Holdings Summary
Pivotal Bioventure Partners Fund I G.p., L.p. currently owns a total of 3 stocks. Among these stocks, Pivotal Bioventure Partners Fund I G.p., L.p. owns 1,794,088 shares of Akouos Inc (AKUS) as of June 30, 2020, with a value of $24 Million and a weighting of 70.38%. Pivotal Bioventure Partners Fund I G.p., L.p. owns 1,571,741 shares of Inozyme Pharma Inc (INZY) as of August 1, 2023, with a value of $7 Million and a weighting of 21.99%. Pivotal Bioventure Partners Fund I G.p., L.p. also owns 1,180,178 shares of Entasis Therapeutics Holdings Inc (ETTX) as of September 28, 2018, with a value of $3 Million and a weighting of 7.63%.
Latest Holdings of Pivotal Bioventure Partners Fund I G.p., L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| AKUS | Akouos Inc | 2020-06-30 | 1,794,088 | 13.29 | 23,843,430 |
| INZY | Inozyme Pharma Inc | 2023-08-01 | 1,571,741 | 4.74 | 7,450,052 |
| ETTX | Entasis Therapeutics Holdings Inc | 2018-09-28 | 1,180,178 | 2.19 | 2,584,590 |
Holding Weightings of Pivotal Bioventure Partners Fund I G.p., L.p.
Pivotal Bioventure Partners Fund I G.p., L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Pivotal Bioventure Partners Fund I G.p., L.p. has made a total of 1 transactions in Akouos Inc (AKUS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Akouos Inc is the acquisition of 294,117 shares on June 30, 2020, which cost Pivotal Bioventure Partners Fund I G.p., L.p. around $5 Million.
According to the SEC Form 4 filings, Pivotal Bioventure Partners Fund I G.p., L.p. has made a total of 3 transactions in Inozyme Pharma Inc (INZY) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Inozyme Pharma Inc is the acquisition of 833,333 shares on August 1, 2023, which cost Pivotal Bioventure Partners Fund I G.p., L.p. around $4 Million.
According to the SEC Form 4 filings, Pivotal Bioventure Partners Fund I G.p., L.p. has made a total of 0 transactions in Entasis Therapeutics Holdings Inc (ETTX) over the past 5 years. The most-recent trade in Entasis Therapeutics Holdings Inc is the acquisition of 337,724 shares on September 28, 2018, which cost Pivotal Bioventure Partners Fund I G.p., L.p. around $5 Million.
Insider Trading History of Pivotal Bioventure Partners Fund I G.p., L.p.
- 1
Pivotal Bioventure Partners Fund I G.p., L.p. Trading Performance
GuruFocus tracks the stock performance after each of Pivotal Bioventure Partners Fund I G.p., L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Pivotal Bioventure Partners Fund I G.p., L.p. is -10.3%. GuruFocus also compares Pivotal Bioventure Partners Fund I G.p., L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Pivotal Bioventure Partners Fund I G.p., L.p. within 3 months outperforms 2 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Pivotal Bioventure Partners Fund I G.p., L.p.'s insider trading performs compared to the benchmark.
Performance of Pivotal Bioventure Partners Fund I G.p., L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -1.7 | | | | | |
| Relative Return to S&P 500(%) | 0.09 | | | | | |
Pivotal Bioventure Partners Fund I G.p., L.p. Ownership Network
Pivotal Bioventure Partners Fund I G.p., L.p. Owned Company Details
What does Inozyme Pharma Inc do?
Who are the key executives at Inozyme Pharma Inc?
Pivotal Bioventure Partners Fund I G.p., L.p. is the director of Inozyme Pharma Inc. Other key executives at Inozyme Pharma Inc include director & 10 percent owner Robert Lorne Hopfner , COO Matthew Winton , and See Remarks Henric Bjorn Bjarke .
Inozyme Pharma Inc (INZY) Insider Trades Summary
Over the past 18 months, Pivotal Bioventure Partners Fund I G.p., L.p. made 1 insider transaction in Inozyme Pharma Inc (INZY) with a net purchase of 833,333. Other recent insider transactions involving Inozyme Pharma Inc (INZY) include a net purchase of 1,833,697 shares made by Robert Lorne Hopfner , a net sale of 7,523 shares made by Douglas A Treco ,
In summary, during the past 3 months, insiders sold 7,523 shares of Inozyme Pharma Inc (INZY) in total and bought 0 shares, with a net sale of 7,523 shares. During the past 18 months, 7,523 shares of Inozyme Pharma Inc (INZY) were sold and 2,667,030 shares were bought by its insiders, resulting in a net purchase of 2,659,507 shares.
Inozyme Pharma Inc (INZY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Inozyme Pharma Inc Insider Transactions
Pivotal Bioventure Partners Fund I G.p., L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Pivotal Bioventure Partners Fund I G.p., L.p.. You might contact Pivotal Bioventure Partners Fund I G.p., L.p. via mailing address: 501 Second Street, Suite 200, San Francisco Ca 94107.
Discussions on Pivotal Bioventure Partners Fund I G.p., L.p.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
